NCT05275491View on ClinicalTrials.gov

Fibroblast Growth Factor 23 and Sclerostin in Relation to Calcium in COVID-19 Patients

CompletedOBSERVATIONAL
Enrollment

66

Participants

Timeline

Start Date

May 1, 2022

Primary Completion Date

January 1, 2023

Study Completion Date

February 1, 2023

Conditions
COVID-19
Interventions
DIAGNOSTIC_TEST

Calcium

Free calcium serum levels

DIAGNOSTIC_TEST

Fibroblast growth factor 23

Serum level

DIAGNOSTIC_TEST

Sclerostin

Serum level

DIAGNOSTIC_TEST

parathyroid hormone

serum level

Trial Locations (1)

81511

Aswan University hospital, Aswān

All Listed Sponsors
lead

Aswan University Hospital

OTHER